Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma
Open accessPublished version of a preprint
Abstract
Cells lacking the tumor suppressor gene LKB1/STK11 alter their metabolism to match the demands of accelerated growth, leaving them highly vulnerable to stress. However, targeted therapy for LKB1-deficient cancers has yet to be reported. In both Kras/p53/Lkb1 cell lines and a genetically engineered mouse model of Kras/p53/Lkb1–induced lung cancer, much higher rates of DNA damage occur, resulting in increased dependence on Chk1 checkpoint function. Here we demonstrate that short-term treatment with the Chk1 inhibitor AZD7762 reduces metabolism in pembrolizumab tumors, synergizing with the DNA-damaging drug gemcitabine to reduce tumor size in these models. Our results offer preclinical proof of concept for use of a Chk1 inhibitor to safely enhance the efficacy of gemcitabine, particularly in aggressive KRAS-driven LKB1-deficient lung adenocarcinomas. Cancer Res; 77(18); 5068–76. ©2017 AACR.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Cardiac glycosides, which inhibit the ATP1A1 Na+/K+-ATPase, selectively affect LKB1-deficient cells.
“LKB1 deficient cells are selectively vulnerable to inhibition of the ATP1A1 Na+/K+-ATPase by cardiac glycosides162”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [162]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y., Jiang, Q. L., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,351 · see citing works
Self-citationChou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · see citing works
AMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602 · see citing works
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017 · see citing works
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914 · see citing works
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849 · see citing works
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
Mihaylova, M. M., & Shaw, R. J. (2011) · Nature Cell Biology · doi:10.1038/ncb2329 · Cited by 2,923 · see citing works
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · see citing works
Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011) · Science · doi:10.1126/science.1196371 · Cited by 2,600 · see citing works
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246 · see citing works
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.029 · Cited by 1,789 · see citing works
DNA damage-induced cell death by apoptosis
Roos, W. P., & Kaina, B. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.007 · Cited by 1,500 · see citing works
AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress
Jeon, S.-M., Chandel, N. S., & Hay, N. (2012) · Nature · doi:10.1038/nature11066 · Cited by 1,132 · see citing works
LKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064 · see citing works
Self-citationOxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., Yang, J. C.-H., Barrett, J. C., & Jänne, P. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7162 · Cited by 850 · see citing works
Cellular pharmacology of gemcitabine
Mini, E., Nobili, S., Caciagli, B., Landini, I., & Mazzei, T. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj941 · Cited by 842 · see citing works
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.
Sánchez‐Céspedes, M., Parrella, P., Esteller, M., Nomoto, S., Trink, B., Engles, J. M., Westra, W. H., Herman, J. G., & Sidransky, D. (2002) · PubMed · Cited by 626 · see citing works
Shackelford, D. B., Abt, E., Gerken, L., Vasquez, D. S., Seki, A., Leblanc, M., Wei, L., Fishbein, M. C., Czernin, J., Mischel, P. S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.008 · Cited by 585 · see citing works
Cavalcante, L. D. S., & Monteiro, G. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.041 · Cited by 577 · see citing works
Svensson, R. U., Parker, S. J., Eichner, L. J., Kolar, M. J., Wallace, M., Brun, S. N., Lombardo, P. S., Van Nostrand, J. L., Hutchins, A., Vera, L., et al. (2016) · Nature Medicine · doi:10.1038/nm.4181 · Cited by 536 · see citing works
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446 · cited 3× · see citing works
“We thank Dr. Yuchuan Wang for 18 F-FDG-PET/CT image study.”
Self-citationVansteenkiste, J., Stroobants, S. G., Dupont, P. J., Leyn, P. R. D., Verbeken, E. K., Deneffe, G. J., Mortelmans, L. A., & Demedts, M. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3201 · Cited by 434 · see citing works
Prevalence and specificity of LKB1 genetic alterations in lung cancers
Matsumoto, S., Iwakawa, R., Takahashi, K., Kohno, T., Nakanishi, Y., Matsuno, Y., Suzuki, K., Nakamoto, M., Shimizu, E., Minna, J. D., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210418 · Cited by 278 · see citing works
Loss of the Tumor Suppressor LKB1 Promotes Metabolic Reprogramming of Cancer Cells via HIF-1α
Faubert, B., Vincent, E. E., Griss, T., Samborska, B., Izreig, S., Svensson, R. U., Mamer, O. A., Avizonis, D., Shackelford, D. B., Shaw, R. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1312570111 · Cited by 278 · see citing works
Somatic LKB1 Mutations Promote Cervical Cancer Progression
Wingo, S. N., Gallardo, T. D., Akbay, E. A., Liang, M., Contreras, C. M., Boren, T., Shimamura, T., Miller, D. S., Sharpless, N. E., Bardeesy, N. M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005137 · Cited by 274 · see citing works
Self-citationBijnsdorp, I. V., Giovannetti, E., & Peters, G. J. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-080-5_34 · Cited by 255 · see citing works
Anticancer therapy with checkpoint inhibitors: what, where and when?
Garrett, M. D., & Collins, I. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.014 · Cited by 204 · see citing works
mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome
Shackelford, D. B., Vasquez, D. S., Corbeil, J., Wu, S., Leblanc, M., Wu, C., Vera, D. R., & Shaw, R. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900465106 · Cited by 204 · see citing works
Sausville, E. A., LoRusso, P. M., Carducci, M. A., Carter, J., Quinn, M. F., Malburg, L., Azad, N. S., Cosgrove, D., Knight, R., Barker, P. N., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2380-5 · Cited by 192 · see citing works
Self-citationLiu, Y., Marks, K. M., Cowley, G. S., Carretero, J., Liu, Q., Nieland, T. J. F., Xu, C., Cohoon, T. J., Gao, P., Zhang, Y., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0015 · Cited by 151 · see citing works
Self-citationALK inhibitors in non-small cell lung cancer: the latest evidence and developments
Sullivan, I., & Planchard, D. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015617355 · Cited by 133 · see citing works
LKB1/STK11 Inactivation Leads to Expansion of a Prometastatic Tumor Subpopulation in Melanoma
Liu, W., Monahan, K. B., Pfefferle, A. D., Shimamura, T., Sorrentino, J., Chan, K. T., Roadcap, D. W., Ollila, D. W., Thomas, N. E., Castrillon, D. H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.048 · Cited by 127 · see citing works
Self-citationThompson, R. H., & Eastman, A. R. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12139 · Cited by 122 · see citing works
Targeting DNA repair, DNA metabolism and replication stress as anti‐cancer strategies
Puigvert, J. C., Sanjiv, K., & Helleday, T. (2015) · FEBS Journal · doi:10.1111/febs.13574 · Cited by 114 · see citing works
Seto, T., Esaki, T., Hirai, F., Arita, S., Nosaki, K., Makiyama, A., Kometani, T., Fujimoto, C., Hamatake, M., Takeoka, H., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2234-6 · Cited by 104 · see citing works
Kaufman, J. M., Amann, J. M., Park, K., Arasada, R. R., Li, H., Shyr, Y., & Carbone, D. P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000173 · Cited by 87 · see citing works
Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh
Neal, J. W., & Sequist, L. V. D. (2010) · Current Treatment Options in Oncology · doi:10.1007/s11864-010-0120-6 · Cited by 53 · see citing works
Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
Hayashi, H., Kurata, T., & Nakagawa, K. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s6252 · Cited by 42 · see citing works
Cardiac glycosides display selective efficacy for STK11 mutant lung cancer
Kim, N., Yim, H. Y., He, N., Lee, C., Kim, J.-H., Choi, J., Lee, H. S., Kim, S., Jeong, E., Song, M., et al. (2016) · Scientific Reports · doi:10.1038/srep29721 · Cited by 38 · see citing works
Kaufman, J. M., Yamada, T., Park, K., Timmers, C. D., Amann, J. M., & Carbone, D. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1639 · Cited by 31 · see citing works
LKB1 inactivation sensitizes non-small cell lung cancer to pharmacological aggravation of ER stress
Inge, L. J., Friel, J. M., Richer, A. L., Fowler, A. J., Whitsett, T. G., Smith, M. A., Tran, N. L., & Bremner, R. M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.011 · Cited by 24 · see citing works
Wang, Y., & Kung, A. L. (2015) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot078246 · Cited by 4 · see citing works
Flagged first, then by citations
1 of the 43 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019 · see citing works
Exploiting DNA Replication Stress for Cancer Treatment
Ubhi, T., & Brown, G. W. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3631 · Cited by 227 · see citing works
Ribonucleotide Reductases: Structure, Chemistry, and Metabolism Suggest New Therapeutic Targets
Greene, B. L., Kang, G., Cui, C., Bennati, M., Nocera, D. G., Drennan, C. L., & Stubbe, J. (2020) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111843 · Cited by 228 · see citing works
LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer
Bonanno, L., Zulato, E., Pavan, A., Attili, I., Pasello, G., Conte, P., & Indraccolo, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081874 · Cited by 52 · see citing works
STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications
Krishnamurthy, N., Goodman, A. M., Barkauskas, D. A., & Kurzrock, R. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.01.050 · Cited by 50 · see citing works
Nunes, C., Depestel, L., Mus, L. M., Keller, K. M., Delhaye, L., Louwagie, A., Rishfi, M., Whale, A. J., Kara, N., Andrews, S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn1382 · Cited by 47 · see citing works
Wang, Y., Li, N., Jiang, W., Deng, W., Ye, R., Cai, X., Qiao, Y., Sharma, A., Zhang, M., Hung, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1489 · Cited by 47 · see citing works
Koh, S., Wallez, Y., Dunlop, C. R., Fernández, S. B. D. Q., Bapiro, T. E., Richards, F. M., & Jodrell, D. I. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3932 · Cited by 40 · see citing works
In silico drug repositioning based on drug-miRNA associations
Zhou, X., Dai, E., Song, Q., Ma, X., Meng, Q., Jiang, Y., & Jiang, W. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz012 · Cited by 36 · see citing works
Synthetic lethality: a step forward for personalized medicine in cancer
Jariyal, H., Weinberg, F. D., Achreja, A., Nagarath, D., & Srivastava, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.014 · Cited by 30 · see citing works
CHEK2 signaling is the key regulator of oocyte survival after chemotherapy
Emori, C., Boucher, Z., & Bolcun‐Filas, E. (2023) · Science Advances · doi:10.1126/sciadv.adg0898 · Cited by 34 · see citing works
Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation
Yu, X., Li, W., Liu, H., Deng, Q., Wang, X., Hu, H., Xu-Monette, Z. Y., Xiong, W., Lu, Z., Young, K. H., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00869-3 · Cited by 30 · see citing works
Self-citationEun, K., Park, M. G., Jeong, Y. W., Jeong, Y. I., Hyun, S., Hwang, W. S., Kim, S.-H., & Kim, H. (2019) · BMC Biotechnology · doi:10.1186/s12896-018-0491-5 · Cited by 29 · see citing works
Goss, K. L., Koppenhafer, S. L., Waters, T. W., Terry, W. W., Wen, K., Wu, M., Ostergaard, J., Gordon, P. M., & Gordon, D. J. (2020) · Oncogene · doi:10.1038/s41388-020-01552-0 · Cited by 27 · see citing works
LKB1: Can We Target an Hidden Target? Focus on NSCLC
Ndembe, G., Intini, I., Perin, E., Marabese, M., Caiola, E., Mendogni, P., Rosso, L., Broggini, M., & Colombo, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.889826 · Cited by 24 · see citing works
Galán‐Cobo, A., Vokes, N. I., Qian, Y., Molkentine, D. P., Ramkumar, K., Paula, A. G., Pisegna, M. A., McGrail, D. J., Poteete, A., Cho, S.-N., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.06.011 · Cited by 27 · see citing works
Zuo, W., Zhang, W., Xu, F., Zhou, J., & Bai, W. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0934-7 · Cited by 26 · see citing works
Park, Y. H., Kim, D., Kim, H. W., Kim, H. S., Lee, D., Lee, M. B., Min, K. Y., Koo, J., Kim, S. J., Kang, C., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.05.012 · Cited by 21 · see citing works
Ji, D., Zhong, X., Huang, P., Kang, P., Leng, K., Zheng, W., Wang, Z., Xu, Y., & Cui, Y. (2020) · Aging · doi:10.18632/aging.103327 · Cited by 21 · see citing works
The role of STK11/LKB1 in cancer biology: implications for ovarian tumorigenesis and progression
Kang, J., Gallucci, S., Pan, J., Oakhill, J. S., & Sanij, E. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1449543 · Cited by 21 · see citing works
Chen, T., Tongpeng, S., Lu, Z., Topatana, W., Juengpanich, S., Li, S., Hu, J., Cao, J., Lee, C., Tian, Y., et al. (2022) · Aging and Cancer · doi:10.1002/aac2.12047 · Cited by 13 · see citing works
Xu, J., Wang, Y., Kauffman, A. E., Zhang, Y., Li, Y., Zhu, J., Maratea, K. A., Fabre, K. M., Zhang, Q., Woodruff, T. K., et al. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa118 · Cited by 12 · see citing works
Self-citationDesign of combination therapy for engineered bacterial therapeutics in non-small cell lung cancer
Deb, D., Wu, Y., Coker, C., Harimoto, T., Huang, R., & Danino, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-26105-1 · Cited by 11 · see citing works
Zhao, Q., Zeng, R., Bi, T., Yang, X., Wang, T., Chen, L., Huang, J., Dai, X., Xu, H., Sun, Q., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c18202 · Cited by 9 · see citing works
Cao, Q., Wang, H., Zhu, J., Chen, Q., Huang, H., & Chu, X. (2023) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023287 · Cited by 7 · see citing works
Chen, J., Shan, T., Wei, T., Jiang, Q., Du, C., Gu, L., Yang, T., Zhou, L., Wang, S., Bao, Y.-L., et al. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03611-3 · Cited by 5 · see citing works
Nunes, C., Depestel, L., Mus, L. M., Keller, K. M., Delhaye, L., Louwagie, A., Rishfi, M., Dolman, M. E. M., Olexiouk, V., Bartenhagen, C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.25.397323 · Cited by 5 · see citing works
Wei, S., Zhou, J., & Dong, B. (2024) · Hereditas · doi:10.1186/s41065-024-00355-7 · Cited by 4 · see citing works
Yu, M., Yang, D., Zhu, D., Wang, Y., Cao, M., Zhu, J., Zhu, W., Wang, G., & Aa, J. (2025) · The Journal of Pathology · doi:10.1002/path.6442 · Cited by 2 · see citing works
Stochastic variation in the FOXM1 transcription program mediates replication stress tolerance
Segeren, H. A., Wierenga, K. A., Riemers, F. M., van Liere, E. A., & Westendorp, B. (2025) · Molecular Oncology · doi:10.1002/1878-0261.13819 · Cited by 1 · see citing works
Yan, P., Jiang, W., Xue, X., Hou, T., Wang, J., Huang, D., Chen, L., Inuzuka, H., Dai, X., & Wei, W. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218678 · Cited by 1 · see citing works
Alkaç, İ. M., İşbilen, M., Küçükkaraduman, B., Gure, A. O., & Vural, B. (2022) · Experimed · doi:10.26650/experimed.1082020
Mai, L., Yang, X., Shao, C., Yu, H., Du, F., Liu, J., Guan, Y., Li, H., Yang, M., Meng, H., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149083
- Authors
- Liu, Y., Li, Y., Wang, X., Liu, F., Gao, P., Quinn, M. M., Li, F., Merlino, A. A., Benes, C., Liu, Q., Gray, N. S., & Wong, K.-K.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Shandong University (CN)
- Chinese Academy of Sciences (CN)
- Massachusetts General Hospital (US)
- NYU Langone Health (US)
- Corresponding author
- Wong, Kwok-Kin
- ORCID
- Venue
- Cancer Research
- Published
- 2017-09-14
- Volume
- 77
- Issue
- 18
- Pages
- 5068-5076
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC5600859
- OpenAlex
- W2741613334
- Cited by
- 33
- References
- 43
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 1 · 2020: 6 · 2019: 7 · 2018: 3
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5u01ca213333-04, 5r01ca205150-04)
- National Cancer Institute (R01-CA205150, R01CA166480, R01CA122794, R01CA195740, R01CA140594, U01-CA213333, R01CA163896)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- gemcitabine, AZD7762, CHK1 inhibitor, lung adenocarcinoma, KRAS-driven lung cancer, p53, DNA damage response, DNA damage checkpoint, drug synergy, cancer metabolism, pembrolizumab, immune checkpoint inhibitors, genetically engineered mouse models
- MeSH terms
- Checkpoint Kinase 1, AMP-Activated Protein Kinase Kinases, Gemcitabine, Adenocarcinoma, Animals, Antimetabolites, Antineoplastic, Carcinoma, Non-Small-Cell Lung, Deoxycytidine, Drug Synergism, Drug Therapy, Combination, Female, Humans, Lung Neoplasms, Mice, Nude, Thiophenes, Tumor Cells, Cultured, Biomarkers, Tumor, Urea, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras), Apoptosis, Protein Serine-Threonine Kinases, Mice, Knockout, Xenograft Model Antitumor Assays, Protein Kinase Inhibitors, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
